AR121661A2 - Esteroides neuroactivos, composiciones y usos de los mismos - Google Patents
Esteroides neuroactivos, composiciones y usos de los mismosInfo
- Publication number
- AR121661A2 AR121661A2 ARP210100747A ARP210100747A AR121661A2 AR 121661 A2 AR121661 A2 AR 121661A2 AR P210100747 A ARP210100747 A AR P210100747A AR P210100747 A ARP210100747 A AR P210100747A AR 121661 A2 AR121661 A2 AR 121661A2
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- alkyl
- alkoxy
- xra
- nrbrc
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
- C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen esteroides 19-nor C3,3-disustituidos de fórmula (1) y sus sales farmacéuticamente aceptables; en donde R¹, R², R³ y R⁴ tienen los valores que se definen en la presente, y A es un sistema de anillos heteroarilo que comprende 3 ó 4 nitrógenos como aquí se define. Se contempla que dichos compuestos son útiles para la prevención y tratamiento de diversos trastornos relacionados con el sistema nervioso central, por ejemplo, el tratamiento de trastornos del sueño, trastornos del estado de ánimo, trastornos del espectro de la esquizofrenia, trastornos convulsivos, trastornos de la memoria y/o la cognición, trastornos del movimiento, trastornos de la personalidad, trastornos del espectro del autismo, dolor, lesiones traumáticas cerebrales, enfermedades vasculares, trastornos del abuso de sustancias y/o síndrome de abstinencia y tinnitus. Reivindicación 1: Un compuesto, caracterizado porque es de la fórmula (1) o una sal farmacéuticamente aceptable del mismo; en donde: A se selecciona del grupo: de compuestos (A-1) - (A-5) del grupo de fórmulas (2); R¹ es C₁-C₆ haloalquilo o C₁-C₆ alquilo; R² y R³ se seleccionan de manera independiente entre H, halo, C₁-C₆ alquilo o alcoxi; R⁴ es halo, ciano, nitro, -S(O)ˣRᵃ, -NRᵇRᶜ, C₁-C₆ alquilo, C₁-C₆ alcoxi, -C(O)Rᵃ, -C(O)ORᵃ o -C(O)NRᵇRᶜ; Rᵃ es H, arilo, heteroarilo o C₁-C₆ alquilo; cada Rᵇ y Rᶜ es de manera independiente H, -S(O)ˣRᵃ, -C(O)Rᵃ, C₁-C₆ alquilo o C₁-C₆ alcoxi, o Rᵇ y Rᶜ tomados junto con el átomo al cual están unidos forman un anillo; n es un número entero entre 0 y 2; y n es un número entero entre 0 y 2; en donde cuando A es (A-1) o (A-2), entonces R¹ se selecciona entre: -CHF₂, -CH₂F, -CCl₃, -CHCl₂, -CH₂Cl, -CBr₃, -CHBr₂, -CH₂Br o C₁-C₆ alquilo; o cuando A es (A-3) o (A-5), R¹ es -CH₃, -CH₂F, -CH₂OCH₃ o -CHF₂, y n es 0, entonces por lo menos uno entre R² y R³ no es H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014078820 | 2014-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121661A2 true AR121661A2 (es) | 2022-06-29 |
Family
ID=54698130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101717A AR100691A1 (es) | 2014-05-29 | 2015-05-29 | Esteroides neuroactivos, composiciones, y usos de los mismos |
| ARP210100747A AR121661A2 (es) | 2014-05-29 | 2021-03-25 | Esteroides neuroactivos, composiciones y usos de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101717A AR100691A1 (es) | 2014-05-29 | 2015-05-29 | Esteroides neuroactivos, composiciones, y usos de los mismos |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20180179247A1 (es) |
| EP (3) | EP3149018B1 (es) |
| JP (4) | JP6652934B2 (es) |
| KR (3) | KR20240066304A (es) |
| CN (3) | CN106661078A (es) |
| AR (2) | AR100691A1 (es) |
| AU (4) | AU2015266447A1 (es) |
| CA (1) | CA2949720A1 (es) |
| CY (1) | CY1124109T1 (es) |
| DK (2) | DK3705488T3 (es) |
| ES (2) | ES2805598T3 (es) |
| HR (2) | HRP20221294T1 (es) |
| HU (2) | HUE059829T2 (es) |
| IL (3) | IL304033A (es) |
| JO (1) | JO3691B1 (es) |
| LT (2) | LT3705488T (es) |
| MX (4) | MX2016015532A (es) |
| PH (1) | PH12016502342A1 (es) |
| PL (2) | PL3705488T3 (es) |
| PT (2) | PT3705488T (es) |
| RS (2) | RS60529B1 (es) |
| RU (2) | RU2019126637A (es) |
| SG (2) | SG10201803812TA (es) |
| SI (2) | SI3149018T1 (es) |
| TW (1) | TW201625661A (es) |
| WO (1) | WO2015180679A1 (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2631233C (en) | 2005-11-28 | 2011-11-08 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| IL286794B2 (en) | 2013-04-17 | 2024-06-01 | Sage Therapeutics Inc | 19- NOR C3, 3- dimomer C21- N- pyrazole Steroids and methods of using them |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RU2754534C2 (ru) | 2013-07-19 | 2021-09-03 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их использование |
| DK3488852T3 (da) | 2013-08-23 | 2021-02-01 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
| ES2805598T3 (es) * | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2016061537A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN107404877A (zh) | 2014-10-16 | 2017-11-28 | 萨奇治疗股份有限公司 | 靶向cns 障碍的组合物和方法 |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| RU2022102537A (ru) * | 2016-03-08 | 2022-03-30 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| AU2017297375B2 (en) | 2016-07-11 | 2022-09-15 | Sage Therapeutics, Inc. | C17, C20, and C21 substituted neuroactive steroids and their methods of use |
| EP3481844B1 (en) * | 2016-07-11 | 2024-04-17 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CA3090724A1 (en) * | 2018-02-11 | 2019-08-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| CN113301901B (zh) * | 2019-01-14 | 2022-09-09 | 北京轩义医药科技有限公司 | 四唑啉酮取代的类固醇及其用途 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| KR20220066262A (ko) | 2019-08-07 | 2022-05-24 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 스테로이드 유도체 조절제의 염 및 결정형 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
| IL304080A (en) | 2021-01-28 | 2023-08-01 | Sage Therapeutics Inc | Use of neuroactive steroids to treat sexual dysfunction |
| EP4377327A1 (en) * | 2021-07-28 | 2024-06-05 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2023164387A1 (en) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of gastrointestinal diseases or conditions |
| WO2024026337A1 (en) | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634717A1 (de) * | 1986-10-11 | 1988-04-14 | Dynamit Nobel Ag | Verfahren zur herstellung von 5-methyltetrazol |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| FR2679263B1 (fr) | 1991-07-15 | 1994-01-14 | Staubli Ets | Perfectionnements aux ratieres a double leve du type hattersley pour machines a tisser. |
| NZ282939A (en) * | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| NZ515779A (en) * | 1999-04-29 | 2003-11-28 | Purdue Pharma Ltd | 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity |
| AU2003301368A1 (en) * | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Scoring of sensed neurological signals for use with a medical device system |
| US7729773B2 (en) * | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
| CA3152410A1 (en) * | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| ES2805598T3 (es) * | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2016061537A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
-
2015
- 2015-05-29 ES ES15799762T patent/ES2805598T3/es active Active
- 2015-05-29 ES ES20171670T patent/ES2927007T3/es active Active
- 2015-05-29 EP EP15799762.8A patent/EP3149018B1/en active Active
- 2015-05-29 CN CN201580039652.9A patent/CN106661078A/zh active Pending
- 2015-05-29 AR ARP150101717A patent/AR100691A1/es active IP Right Grant
- 2015-05-29 CN CN202111131937.9A patent/CN114133423A/zh active Pending
- 2015-05-29 PT PT201716701T patent/PT3705488T/pt unknown
- 2015-05-29 IL IL304033A patent/IL304033A/en unknown
- 2015-05-29 KR KR1020247014858A patent/KR20240066304A/ko active Search and Examination
- 2015-05-29 KR KR1020167036320A patent/KR102494061B1/ko active IP Right Grant
- 2015-05-29 CN CN202110905603.6A patent/CN114369135A/zh active Pending
- 2015-05-29 SG SG10201803812TA patent/SG10201803812TA/en unknown
- 2015-05-29 LT LTEP20171670.1T patent/LT3705488T/lt unknown
- 2015-05-29 HR HRP20221294TT patent/HRP20221294T1/hr unknown
- 2015-05-29 EP EP20171670.1A patent/EP3705488B1/en active Active
- 2015-05-29 CA CA2949720A patent/CA2949720A1/en active Pending
- 2015-05-29 IL IL292461A patent/IL292461B2/en unknown
- 2015-05-29 DK DK20171670.1T patent/DK3705488T3/da active
- 2015-05-29 RS RS20200799A patent/RS60529B1/sr unknown
- 2015-05-29 JP JP2016569716A patent/JP6652934B2/ja active Active
- 2015-05-29 RU RU2019126637A patent/RU2019126637A/ru unknown
- 2015-05-29 TW TW104117532A patent/TW201625661A/zh unknown
- 2015-05-29 SI SI201531252T patent/SI3149018T1/sl unknown
- 2015-05-29 PL PL20171670.1T patent/PL3705488T3/pl unknown
- 2015-05-29 PT PT157997628T patent/PT3149018T/pt unknown
- 2015-05-29 EP EP22187660.0A patent/EP4144746A1/en active Pending
- 2015-05-29 KR KR1020237003114A patent/KR102664412B1/ko active IP Right Grant
- 2015-05-29 WO PCT/CN2015/080216 patent/WO2015180679A1/en active Application Filing
- 2015-05-29 LT LTEP15799762.8T patent/LT3149018T/lt unknown
- 2015-05-29 MX MX2016015532A patent/MX2016015532A/es unknown
- 2015-05-29 SI SI201531879T patent/SI3705488T1/sl unknown
- 2015-05-29 AU AU2015266447A patent/AU2015266447A1/en not_active Abandoned
- 2015-05-29 RU RU2016151727A patent/RU2699359C2/ru active
- 2015-05-29 RS RS20220848A patent/RS63554B1/sr unknown
- 2015-05-29 IL IL248948A patent/IL248948B/en unknown
- 2015-05-29 HU HUE20171670A patent/HUE059829T2/hu unknown
- 2015-05-29 PL PL15799762T patent/PL3149018T3/pl unknown
- 2015-05-29 HU HUE15799762A patent/HUE050028T2/hu unknown
- 2015-05-29 DK DK15799762.8T patent/DK3149018T3/da active
- 2015-05-29 SG SG11201609813XA patent/SG11201609813XA/en unknown
- 2015-05-29 US US15/314,565 patent/US20180179247A1/en active Pending
- 2015-05-31 JO JOP/2015/0132A patent/JO3691B1/ar active
-
2016
- 2016-11-24 PH PH12016502342A patent/PH12016502342A1/en unknown
- 2016-11-25 MX MX2021005106A patent/MX2021005106A/es unknown
- 2016-11-25 MX MX2023004352A patent/MX2023004352A/es unknown
- 2016-11-25 MX MX2021005099A patent/MX2021005099A/es unknown
-
2019
- 2019-12-09 AU AU2019279910A patent/AU2019279910B2/en active Active
-
2020
- 2020-01-24 JP JP2020009771A patent/JP6892936B2/ja active Active
- 2020-01-31 US US16/778,975 patent/US20200165291A1/en not_active Abandoned
- 2020-07-17 HR HRP20201126TT patent/HRP20201126T1/hr unknown
- 2020-07-27 CY CY20201100683T patent/CY1124109T1/el unknown
- 2020-11-10 US US17/094,783 patent/US20210061849A1/en not_active Abandoned
- 2020-11-13 US US17/097,569 patent/US20210061850A1/en not_active Abandoned
-
2021
- 2021-03-25 AR ARP210100747A patent/AR121661A2/es unknown
- 2021-05-28 JP JP2021089953A patent/JP7386204B2/ja active Active
- 2021-06-28 AU AU2021204410A patent/AU2021204410B2/en active Active
-
2023
- 2023-07-10 JP JP2023113247A patent/JP2023123878A/ja active Pending
- 2023-10-06 US US18/482,079 patent/US20240076310A1/en active Pending
- 2023-12-19 AU AU2023285755A patent/AU2023285755A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR101177A1 (es) | Inhibidores de la syk | |
| PE20150399A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| MA37213B1 (fr) | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| AR088000A1 (es) | Derivados de pirazolquinolinona, su preparacion y su uso terapeutico | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100775A1 (es) | Compuestos pesticidas y procedimientos relacionados con los mismos | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| CR20190236A (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR096709A1 (es) | Ligandos sigma para la prevención y el tratamiento de dolor asociado a cistitis intersticial / síndrome de dolor vesical (ci / sdv) | |
| AR099047A1 (es) | Derivados etinilo | |
| AR120040A1 (es) | Compuesto heterocíclico | |
| PE20160241A1 (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| EA201692264A1 (ru) | Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a | |
| AR099529A1 (es) | Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer | |
| PE20190778A1 (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiamida |